Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3158771 | 1.00 | MAPT (0.41) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3164586 | 0.90 | MAPT (0.41) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3164576 | 0.90 | MAPT (0.41) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3178609 | 0.89 | CPT1A (0.44) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3178620 | 0.89 | CPT1A (0.44) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL29950591 | 0.83 | HSP90AA1 (0.43) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL6170617 | 0.82 | MAPT (0.46) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL6170611 | 0.82 | MAPT (0.46) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL6139345 | 0.79 | HDAC3 (0.43) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL3168219 | 0.79 | GRM5 (0.44) | MAPTMEN1KMT2AKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-20060173004-A1 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG (CH) | 2006-08-03 | — | — | US | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| EP-1558594-A2 | 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES | Novartis AG (CH) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004037796-A2 | 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES | NOVARTIS AG (CH) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173004-A1 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | CCR1, CCR3, CCR4 | MAPT 2279/4885MEN1 3038/4885KMT2A 4287/4885 |
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | MAPT 2220/4885MEN1 3157/4885KMT2A 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.